Search Results

Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer.

• Authors : Kashiwa M; Faculty of Pharmacy, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan. .; Comprehensive Unit for Health Economic Evidence Review and Decision Support, Ritsumeikan University, Kyoto, Japan. .

Subjects: Cisplatin*/Cisplatin*/Cisplatin*/economics ; Cisplatin*/Cisplatin*/Cisplatin*/therapeutic use ; Cisplatin*/Cisplatin*/Cisplatin*/administration & dosage

• Source: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2024 Dec; Vol. 55 (4), pp. 1569-1580. Date of Electronic Publication: 2024 Aug 22.Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.

• Authors : Mitsui Y; Department of Urology, Toho University Faculty of Medicine, Tokyo, Japan.; Okawa M

Subjects: Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/drug therapy ; Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/pathology ; Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/Urinary Bladder Neoplasms*/mortality

• Source: International journal of urology : official journal of the Japanese Urological Association [Int J Urol] 2024 Sep; Vol. 31 (9), pp. 1030-1037. Date of Electronic Publication: 2024 Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 9440237 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Japan Clinical Trial: St.Marry Hospital Registers Clinical Trial to Study Gemcitabine, Dexamethasone, Cisplatin, and Rituximab (GDP-R) Plus Epcoritamab Therapy for Older Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell Lymphoma.

• Source: Contify Life Science News. 2024.

Record details

Opdivo Intravenous Infusion Approved in Taiwan in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma.

• Source: Contify Life Science News. 2024.

Record details

Ono Pharmaceutical - Opdivo Intravenous Infusion Approved in Taiwan in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma.

• Source: ENP Newswire. October 11, 2024.

Record details

Bristol Myers Squibb Receives European Commission Approval for Opdivo in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma.

• Source: Contify Life Science News. 2024.

Record details

Bristol Myers Squibb Receives European Commission Approval for Opdivo[R] (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma.

• Source: Business Wire. 2024.

Record details

European Medicines Committee adopts positive opinion recommending approval of Bristol-Myers Squibb's Opdivo in combination with cisplatin and gemcitabine as first-line treatment for adult patients with unresectable or metastatic urothelial cancer.

• Source: Contify Life Science News. 2024.

Record details

A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report.

• Authors : Koi, Yumiko; Tajiri, Wakako; Kawasaki, Junji

Subjects: THERAPEUTIC use of antineoplastic agents; BREAST tumor diagnosis; THERAPEUTIC use of monoclonal antibodiesJAPAN

• Source: Thoracic Cancer; Oct2024, Vol. 15 Issue 28, p2073-2076, 4p

Record details

Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel.

• Authors : Wei, Mengyan; Wang, Pu; Zhu, Xiufang

• Source: PLoS ONE. February 2, 2023, Vol. 18 Issue 2, e0280656.

Record details